CGEM · NASDAQ
Cullinan Therapeutics (CGEM) Stock Price & Fundamentals
Cullinan Therapeutics (CGEM) closed at $495.53 on Oct 9, 2026, down 0.80% from the previous close of $499.55.
Share price, past year
1Y +30.73%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $495.53 |
| Sep 30, 2026 | $484.43 |
| Aug 31, 2026 | $483.16 |
| Jul 31, 2026 | $507.53 |
| Jun 30, 2026 | $515.22 |
| May 29, 2026 | $484.29 |
| Apr 30, 2026 | $459.57 |
| Mar 31, 2026 | $443.03 |
| Feb 27, 2026 | $447.41 |
| Jan 30, 2026 | $416.60 |
| Dec 31, 2025 | $409.16 |
| Nov 28, 2025 | $376.74 |
| Oct 31, 2025 | $357.10 |
Key statistics
- Market cap
- $31.89B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$219.88M
- Shares outstanding
- 64.3M
- Dividend yield
- —
- 52-week range
- $357.10 – $521.46
Cullinan Therapeutics's market cap is $31.89B, based on a share price of $495.53 and 64.3M shares outstanding as of Jun 30, 2026.
Financials
Cullinan Therapeutics reported revenue of $0.00 for fiscal 2022, down 100.00% from fiscal 2021.
Cullinan Therapeutics reported a net loss of $219.88M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $0.00 | −100.0% | $111.21M | — | $2.38 | −$127.80M |
| FY2021ended Dec 31, 2021 | $18.94M | — | −$65.57M | −346.1% | −$1.52 | −$43.43M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$51.80M | — | −$2.60 | −$29.78M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | −$0.58 |
| Q3 FY2022ended Sep 30, 2022 | $0.00 | — | — |
| Q2 FY2022ended Jun 30, 2022 | $0.00 | — | — |
| Q1 FY2022ended Mar 31, 2022 | $0.00 | — | — |
| Q4 FY2021ended Dec 31, 2021 | $0.00 | — | — |
| Q3 FY2021ended Sep 30, 2021 | $0.00 | — | — |
| Q2 FY2021ended Jun 30, 2021 | $0.00 | — | — |
| Q1 FY2021ended Mar 31, 2021 | $18.94M | — | — |
Company profile
- Name
- Cullinan Therapeutics, Inc.
- Ticker
- CGEM
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- One Main Street, Suite 1350, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001789972
Recent SEC filings
- Oct 2, 2026
- Sep 24, 2026
- Sep 14, 2026
- Aug 13, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 16, 2026
- Jun 10, 2026
Frequently asked questions
What is Cullinan Therapeutics's stock price?
Cullinan Therapeutics (CGEM) closed at $495.53 on Oct 9, 2026, down 0.80% from the previous close of $499.55.
What is Cullinan Therapeutics's market cap?
Cullinan Therapeutics's market cap is $31.89B, based on a share price of $495.53 and 64.3M shares outstanding as of Jun 30, 2026.
How much revenue does Cullinan Therapeutics make?
Cullinan Therapeutics reported revenue of $0.00 for fiscal 2022, down 100.00% from fiscal 2021.
Does Cullinan Therapeutics pay a dividend?
Cullinan Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Cullinan Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures